TrialBritish journal of clinical pharmacology2011

SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans.

Aili L Lazaar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.